Jeff Yass’s Sagimet Biosciences SGMT Stock Holding History

Jeff Yass’s Portfolio SGMT Stock Details SGMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.44M	Buy	186,400 +99,000	+113%	+$673K	﹤0.01%	7262
2026 Q1	$457K	Buy	87,400 +53,100	+155%	+$296K	﹤0.01%	9911
2025 Q4	$203K	Sell	34,300 -30,500	-47%	-$219K	﹤0.01%	10844
2025 Q3	$445K	Sell	64,800 -13,000	-17%	-$105K	﹤0.01%	9226
2025 Q2	$593K	Buy	77,800 +11,000	+16%	+$46.4K	﹤0.01%	8788
2025 Q1	$218K	Sell	66,800 -104,600	-61%	-$439K	﹤0.01%	10770
2024 Q4	$771K	Buy	171,400 +80,400	+88%	+$407K	﹤0.01%	7600
2024 Q3	$252K	Buy	+91,000	New	+$280K	﹤0.01%	9987

Other funds holding SGMT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Jeff Yass's SGMT Position: Q2 2026 in Review

Jeff Yass reduced its Sagimet Biosciences (SGMT) stake by 91% in Q2 2026, selling an estimated $773K and leaving 10,950 shares worth $84.6K. The position accounts for ﹤0.01% of the portfolio, ranked #12602.

Jeff Yass first reported a position in SGMT in Q1 2024 and has held it in 10 quarters since. The position peaked at $1.08M in Q2 2025. 122 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

Jeff Yass held 10,950 shares of Sagimet Biosciences worth $84.6K as of Q2 2026.
Jeff Yass sold 113,654 Sagimet Biosciences shares in Q2 2026, an estimated $773K.
Sagimet Biosciences made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #12602 holding.
Jeff Yass first reported a position in Sagimet Biosciences in Q1 2024 and has held it in 10 quarters since.
Jeff Yass's Sagimet Biosciences position peaked at $1.08M in Q2 2025.
122 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.